Nucor Corporation vs Zoetis Inc — how do they compare? Nucor Corporation trades at $251.26 (market cap $55.84B), while Zoetis Inc trades at $74.55 (market cap $30.20B). The key difference: Nucor Corporation is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and Zoetis Inc for 70 Days on average.
| NUE | ZTS | |
|---|---|---|
Market Cap | $55.84B | $30.20B |
Volume | 848,835 | 6,175,327 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $147.53 |
52-Week Low | $131.78 | $69.09 |
Typical Hold Time | 78 Days | 70 Days |
Enterprise Value | $60.25B | $37.76B |
Dividend Yield | 0.91% | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $250.98, up 1.84% on the day, showing resilience amid a mixed technical backdrop. Recent earnings have beaten expectations in Q1 and Q2 2026, though Q4 2025 was a miss. The company maintains a strong balance sheet with a debt-to-asset ratio of 20.23% for 2025, and analyst consensus is a Moderate Buy with a $266.88 price target. Revenue is projected to grow to $36.1B in 2026, with net income margin improving to 7.98%.
The outlook for NUE is cautiously optimistic, supported by earnings beats and a solid dividend history, but risks include competitive pressures from new steel capacity and volatile steel prices. The stock's current valuation metrics, such as a P/E of 19.64, appear reasonable relative to historical performance, offering potential upside if earnings guidance is met.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →